Drug-maker Wockhardt today said its consolidated net loss for the quarter ended June 30 narrowed by 38.75 per cent to Rs 116.28 crore.
The Mumbai-based company had posted a net loss of Rs 189.87 crore in the corresponding quarter of the previous fiscal.
Net sales of the company stood at Rs 921.64 crore for the quarter ended June 30, compared to Rs 954.15 crore in the same period of the corresponding fiscal, Wockhardt said in a statement.
Sales of Wockhardt's USA division grew by 17 per cent in April-June, 2010, over the corresponding period of 2009. It received two abbreviated new drug application (ANDA) approvals during the quarter.
The company's UK business grew by 35 per cent compared to the average industry growth of 5.5 per cent in the June quarter of 2010. It also received three product approvals from the UK health regulator during the quarter.
In addition, the company's domestic branded business grew by 16 per cent in the quarter ended June 30 compared to the same period of the previous fiscal.
Shares of Wockhardt today closed at Rs 161 on the Bombay Stock Exchange (BSE), up 3.34 per cent from the previous close.
